Date | Company | Round | Amount | Co-investors |
---|---|---|---|---|
2021-01-07 | Scorpion Therapeutics | Series B | $162M | Abingworth, Boxer Capital, Casdin Capital, EcoR1 Capital, Invus Group, Janus Henderson Investors, Logos Capital, Nextech Invest, Omega Fund Management, OrbiMed Advisors, Surveyor Capital, Vida Ventures, Wellington Management, and Woodline Partners |
2021-01-05 | Ikena Oncology | Series B | $120M | Bristol-Myers Squibb, BVF Partners, Cowen, Farallon Capital Management, Fidelity Investments, HealthCor Management, Invus Group, Logos Capital, Omega Fund Management, OrbiMed Advisors, and Surveyor Capital |
2020-12-08 | Remix Therapeutics | Series A | $81M | Alexandria Venture Investments, ARCH Venture Partners, Foresite Capital, and The Column Group |
2020-11-30 | Kinaset Therapeutics | Series A | $40M | 5AM Ventures, and Gimv |
2020-10-29 | Q32 Bio | Series B | $60M | Abingworth, Acorn Bioventures, Children's Hospital Colorado, OrbiMed Advisors, Osage University Partners, Sanofi Ventures, and University of Colorado |